The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients: a single-center experience

Click to increase image sizeClick to decrease image size

Disclosure statement

Rory Bennett: No conflicts of interest to declare

Henry Chan:

Advisory board – Janssen, Abbvie

Travel grant – Celgene, Amgen, Janssen

Research grant – Amgen, Janssen

Ross Henderson: No conflicts of interest to declare

Eileen Merriman: No conflicts of interest to declare

Merit Hanna: No conflicts of interest to declare

Anna Elinder-Camburn: No conflicts of interest to declare

David Simpson:

Employment stocks – Beigene

Research funding – Abbvie, Amgen, Celgene, Roche MSD, Acerta, Pharmacyclics, Sanofi, Beigene, GSK

Honoraria – Abbvie, Roche, Janssen